Clinical Trials Browser

Phase 2 × Active not recruiting × sacituzumab govitecan × Clear all

NCT03725761 2026-06-04

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Phase 2 Active not recruiting

31 enrolled 12 charts

Prostatic Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

Breast Neoplasms

NCT04647916 2026-05-06

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Phase 2 Active not recruiting

Brain Neoplasms

NCT03964727 2026-04-28

TROPiCS-03

Phase 2 Active not recruiting

227 enrolled 31 charts

Neoplasm Metastasis

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

Urothelial Bladder Carcinoma

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2 Active not recruiting

Breast Neoplasms

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT05186974 2026-02-11

EVOKE-02

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast Neoplasms

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor